BioVie’s stock has moved up considerably over the past 9 months in light of promising Alzheimer’s data. BioVie Day and full Phase 2 Parkinson’s trial results are scheduled for this month. BioVie has ...

Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis.

The MarketWatch News Department was not involved in the creation of this content. -- Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor ...

BASILDON, England--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has ...

The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The ascites ...

in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology Ghent, Belgium – 7 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, ...

Paracentesis is a medical procedure that doctors perform to drain fluid from a person’s abdominal cavity. It is sometimes called an abdominal tap. Doctors refer to this buildup of fluid as ascites, ...

Informal caregiving for older adults on systemic treatment for hepatocellular carcinoma.